Interceptor Spectrum Chews - Yellow. Med Dogs 11-22kg 6 Pack

INTERCEPTOR Spectrum Chews Yellow. Med Dogs 11-22kg 6 pack
INTERCEPTOR® Spectrum is a convenient and simple way to protect your dog against heartworm and the major intestinal worms. One tasty chew monthly all year round is all it takes to give your dog a lifetime of protection against even the most dangerous worm

Interceptor Spectrum is now a monthly palatable Chewable for the prevention of heartworm and the treatment and prevention of roundworm, hookworm and whipworm and tapeworm in dogs.

Actions Milbemycin oxime prevents heartworm and controls gastrointestinal nematodes. It increases nematode membrane permeability to chloride ions via glutamate gated chloride ion channels, leading to flaccid paralysis and death of the parasite. Praziquantel controls tapeworms by modifying the permeability of their membranes to calcium, inducing damage to the membranes and resulting in the death of the parasite.
Indications Monthly treatment prevents heartworm (Dirofilaria immitis) infection, controls adult roundworm (Toxocara canis, Toxascaris leonina), immature roundworm (Toxocara canis), adult whipworm (Trichuris vulpis), adult hookworm (Ancylostoma caninum), adult tapeworm (Echinococcus granulosus, Taenia pisiformis and Dipylidium caninum) and aids in the control of adult hookworm (Uncinaria stenocephala) infection in dogs.
Warnings Some mild, transient, shock-like reactions have occurred when treating heartworm positive dogs carrying a high number of microfilariae at the time of the first treatment with milbemycin oxime. Dogs should be tested and be free from both adult heartworm and microfilariae before starting on preventative treatment with Interceptor Spectrum.
Precautions Interceptor Spectrum provides a wide margin of safety in dogs when used according to label directions. Milbemycin oxime has been tested in over 75 different breeds of dogs, including pregnant females, breeding males and females, and puppies from 2 weeks of age. Satisfactory margins of safety have been demonstrated for both milbemycin oxime and praziquantel when administered during all reproductive phases.